CASE STUDY | MEDICAL COMMUNICATIONS
When Biomarker Testing Lacked Urgency, We Unified the Science.
THE CHALLENGE
Biomarker Testing and Awareness Increase Needed Prior to Launch
A pharmaceutical company preparing for entry into a targeted oncology market needed to effectively communicate the importance of KRAS G12C biomarker testing, a mutation that drives tumor growth and is used to help identify patients for targeted therapies.
While the science was established, testing rates were inconsistent. Medical education communications lacked alignment, limiting clarity and reducing urgency around biomarker testing ahead of launch.
THE BREAKTHROUGH
Shifting from Disconnected Tactics to a Unified Communication System
BGBx identified that fragmented medical education efforts were limiting clarity and urgency around biomarker testing. Rather than adding more tactics, BGBx established a unified scientific platform anchored in a core set of communication points, ensuring every interaction reinforced one clinical narrative.
This platform was deployed across all channels, including field resources, CDx toolkits, symposia, webinars, and scientific content, aligning U.S. and global teams under a single framework. By standardizing how the science was communicated, we transformed dispersed activities into a coordinated system, driving clarity, consistency, and urgency around biomarker testing.
THE RESULTS
Increased Awareness and Biomarker Testing Prior to Launch
A significant increase in baseline awareness of KRAS G12C was achieved, alongside improved alignment and consistency across medical education communications.
~80%
Biomarker Testing Rate
Achieved pre-launch goal
Our Perspectives on Advertising
2026 Oncology Market Access Trends
Implications of the IRA’s Maximum Fair Price (MFP) Negotiations
340B Drug Discount Program
Let’s Build the Scientific Foundation for Your Next Launch
At BGBx, we develop scientific platforms that create alignment and consistency across medical communications to support effective education and engagement. Let’s build your next breakthrough together.
